management to date. As of March 2021 mortality was only 1% with just a single patient dying of a suspected dysrhythmia. There is a lack of international guideline on timing of follow up investigation in routine management of channelopathies, but our cohort suggests that routine Holter monitoring in asymptomatic LQTS and BrS does not significantly alter sudden cardiac death (SCD) risk management. We educate our ICC channelopathy patients' to report their symptoms to facilitate prompt rhythm assessment, and given pressures on current health systems, perhaps focusing on these symptomatic patients would be an appropriate use of resources.

28 OUR LEFT BUNDLE BRANCH PACING EXPERIENCE: A SINGLE CENTRE STUDY

R Walsh, F Kehoe, S Frohlich, N Murphy, J Lyne. *Beacon Hospital, Dublin, Ireland*

10.1136/heartjnl-2021-ICS.28

Background Chronic ventricular pacing results in dyssynchronous ventricular activation and may result in pacing-induced cardiomyopathy. Conduction system pacing (CSP) allows for physiologic ventricular activation. Left bundle branch pacing (LBBp) has emerged in recent time as an alternative to His-bundle pacing. It offers the physiological ventricular activation while avoiding the difficulty in targeting the His-bundle and maintaining stable long term lead parameters. Here we describe our experience LBBp.

Objective To describe the LBBp experience and compare the learning curve associated with LBBp to that described with His-bundle pacing.

Methods This study is a retrospective and observational study. Our patient cohort of 90 patients was collected between November 2019 to March 2021. We included all patients who underwent LBBp in this period and examined them at 2 and 6 months post operatively. We further divided these patients into four quartiles to further examine our learning curve. They were examined on age, gender, diagnosis, co-morbidities, NYHA score, tricuspid regurgitant velocity, LVEF, LVEDd, procedure time, fluoroscopy time, and complications. We examined pre- and post- QRS, pre- and post- QRS axis, selective LBBp at implant and follow up, and implant pacemaker parameters and at follow-up. Data was collected and analysed.

Results A total of 64.5% of patients were male, mean age was 76 years. 15.1±37% were LBBB with HF, 51.1±% were AVN block/AF with AVN ablation, and 30.2% were sick sinus syndrome. The majority of patients were NYHA I or II. The mean EF preimplant was 48.3%. Average pre- and immediate post- QRS was 126.7ms and 126.4ms respectively. At a mean follow up of 5 months QRS average was 119.3ms. Mean thresholds at follow up were 0.73±0.35mV, 0.72±0.22mV, and 0.8±0.27mV at implant, 2 months, and 6 months respectively. Mean procedure time was 71±31.9 minutes, with a mean fluoroscopy time of 11.7±8.6 minutes. One patient required lead revision with displacement from the interventricular septum, one patient had a mild mediastinal bleed requiring transfusion, and 3 patients that failed LBBp insertion and were converted to standard techniques. No septal perforation, tricuspid valve injury, AV fistula or other pacemaker complication occurred. No complications were seen during follow-up.

Conclusion Left bundle branch pacing offers a potential improvement on His-bundle pacing. Thresholds at implant

were considerably lower, remained stable during follow-up, and sensing was improved compared to His-bundle pacing. Procedure time reduced as our experience grew, this varied with type of device inserted, as well as fluoroscopy time. Left bundle branch pacing is accessible with a comparable learning curve to His-bundle pacing. However, further large multi-centre studies are needed to evaluate left bundle branch pacing further.

29 THE ASSOCIATION BETWEEN NOVEL ST2, BNP, ATRIAL FIBRILLATION AND HEART FAILURE

K Al-Wahaibi, I Khan, M Smith, T Leong. *Hermitage Medical Clinic, Dublin, Ireland*

10.1136/heartjnl-2021-ICS.29

Background/Introduction ST2, a novel marker of fibrosis has been proposed as a novel biomarker for heart failure. There is paucity of data suggesting its association with Atrial Fibrillation (AF), in particular, with regards to the its independent effect after adjustment for clinical factors and traditional biomarkers such as BNP. There is increasing evidence that inflammation and fibrosis are important players in the pathogenesis of AF, the most common arrhythmia that is associated with considerable morbidity. Purpose We sought to examine the association of ST2 with AF and its possible incremental value in combination with traditional biomarkers already used in routine clinical practice such as BNP.

Methods Unselected patients presenting to a Cardiology service who had BNP for clinical reasons, concomitantly had ST2 sent. These patients included those with heart failure, acute coronary syndromes and AF, as well as patients attending cardioversion and cardiac catheterisation. The association between ST2, BNP and clinical factors was examined. ST2 was examined in tertiles as its distribution was highly skewed. Raised BNP was defined as usual (≥ 100 pg/ml).

Results Of the 619 patients, the mean age was 69 years and 66% were male. The prevalence of co-morbidities were: Coronary heart disease – CHD (41%), Atrial Fibrillation – AF (30%), Heart Failure – HF (20%), Chronic Kidney Disease – CKD (23%). The mean eGFR was 68 ml/h and the mean LV ejection fraction was 55%. Both ST2 and BNP levels were significantly higher in patients with heart failure, CKD and AF. Mean levels of ST2 were (in ng/ml): HF vs no HF (65 vs. 38, $p = 0.0001$) and in CKD vs. no CKD (49 vs. 41, $p = 0.001$), CAD vs no CAD (43 vs. 42, $p = 0.3$). Mean levels of BNP were (in pg/ml): HF vs no HF (579 vs. 131, $p = 0.0001$), CKD vs. no CKD (379 vs. 173, $p = 0.0001$), CAD vs. no CAD (239 vs. 206, $p = 0.5$). In patients with AF, levels of both ST2 and BNP were higher, as were their mean ages

Abstract 29 Table 1 Comparison between patients without AF and AF

	No AF	AF	P value
Age in years (SD)	67 (10)	75 (9)	<0.0001
Male sex	65%	69%	0.44
Comorbidities/Risk Factors			
Chronic heart failure	13%	36%	<0.0001
Chronic kidney disease	18%	34%	0.003
Coronary heart disease	46%	29%	0.001
LV EF (SD)	65% (13%)	53% (11%)	0.005
Biomarkers			
BNP (pg/ml)	158	370	<0.0001
ST2 (ng/ml)	40	50	<0.0001
hs-TnI (ng/L)	454	689	0.03
Creatinine (μmol/L)	90	108	<0.0001
eGFR (mL/min/1.73m ²)	67	60	<0.0001